🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

59 results for “Vera” Clear

  1. Atacicept

    Vera Therapeutics

    IgA Nephropathy

    phase 3 mab active

    1 trial

  2. Atacicept

    Vera Therapeutics

    Lupus Nephritis (LN)

    phase 3 small molecule terminated

    1 trial

  3. DANAZOL , BUSULFAN , -, POMALIDOMIDE , FEDRATINIB, RUXOLITINIB, PEGFILGRASTIM , HYDROXYCARBAMIDE , PEGINTERFERON ALFA-2A , -

    Celgene Europe Limited

    Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-essential thrombocythemia myelofibrosis

    phase 3 small molecule active

    1 trial

  4. DAPAGLIFLOZIN, Placebo for dapagliflozin film-coated tablets 10 mg

    Disc Medicine

    Combined endpoint of all-cause mortality, kidney failure, and hospitalization for heart failure in the overall study population

    phase 3 small molecule active

    1 trial

  5. DR-3001

    Teva Pharma GmbH

    Overactive Bladder

    phase 3 small molecule completed

    1 trial

  6. Givinostat 50 mg capsules, RIVAROXABAN , ACETYLSALICYLIC ACID , Givinostat 100 mg capsules, HYDROXYCARBAMIDE, ENOXAPARIN , -, Givinostat 75 mg capsules, DABIGATRAN ETEXILATE

    Italfarmaco S.p.A.

    JAK2V617F-positive high-risk Polycythemia Vera

    phase 3 small molecule active

    1 trial

  7. Immune Globulin 10% Intravenous Solution

    Vera Therapeutics

    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  8. LGP PURE CBD 200, caprylic/capric triglyceride liquid

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Patients with stage I, II, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory)

    phase 3 small molecule active

    1 trial

  9. LGP PURE CBD 200, caprylic/capric triglyceride liquid

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Patients with stage I, II, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory)

    phase 3 small molecule active

    1 trial

  10. MK-3543, MK-3543, MK-3543, MK-3543

    Merck Sharp and Dohme

    Myeloproliferative Neoplasms (Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis)

    phase 3 small molecule active

    1 trial

  11. Mirabegron

    Astellas Pharma GmbH

    Neurogenic detrusor overactivity (NDO)

    phase 3 small molecule active

    1 trial

  12. Open-label rusfertide

    Protagonist Therapeutics, Inc

    Polycythemia Vera

    phase 3 small molecule active

    1 trial

  13. Oxybutinyn Vaginal Ring 4mg

    Teva Pharma GmbH

    Overactive Bladder

    phase 3 small molecule completed

    1 trial

  14. PROTAMINE CHOAY 1000 U.A.H./ml, solution injectable

    Pari Pharma GmbH

    Any patients ≥18 years old, eligible for transfemoral TAVI with coverage for medical insurance

    phase 3 small molecule active

    1 trial

  15. Placebo

    Protagonist Therapeutics, Inc

    Polycythemia Vera

    phase 3 small molecule active

    1 trial

  16. Rusfertide 45mg, Rusfertide 60mg, Rusfertide 30mg, Rusfertide 10mg, Rusfertide 20mg, Placebo to Match PTG-300 for Injection. Formulation (lyophilized powder) is based upon that of PTG-300 for Injection, with the drug substance omitted.

    Protagonist Therapeutics, Inc

    Polycythemia Vera

    phase 3 small molecule active

    1 trial

  17. Sativex®

    Jazz Pharmaceuticals Ireland Limited

    Detrusor Overactivity

    phase 3 small molecule completed

    1 trial

  18. Sildenafil placebo, Remidia, 20 mg, tabletki powlekane

    Cardiol Therapeutics

    Patients with functionally single ventricle (FSV - functionally single ventricle) after Fontan operation. The term "functionally single ventricle" refers to congenital heart defects in which one of the ventricles is not fully developed and/or one of the valves is atresia/hypoplastic as a result, it is not possible to correct the intracardiac defect. Then, there are indications for the Fontan operation, i.e. a palliative procedure - total cavo-pulmonary connection (TCPC). In patients with a functionally single ventricle, more than one operation is necessary to separate the systemic and pulmonary circulation. As a result of these procedures, Fontan circulation is created, which consists in bypassing the right heart chambers and directing the venous blood to the pulmonary artery. This leads to the removal of the right-to-left shunt and improvement of arterial blood saturation and reduction of volume overload of the systemic ventricle. At the same time, there is an increase in systemic venous pressure and a decrease in cardiac output. Low pulmonary resistance in these patients is crucial for maintaining optimal hemodynamic conditions both at rest and especially during exercise. Even a slight increase in pulmonary resistance leads to reduced pulmonary blood flow, reduced initial depression of a single ventricle, and consequently to reduced cardiac output and worsened exercise tolerance. Thus, pulmonary resistance in these patients should be not only normal, but also as low as possible to ensure adequate single ventricular filling and adequate cardiac output. There is evidence that patients with Fontan surgery increase pulmonary resistance over time. The increase in pulmonary resistance in these patients may result from several factors, and above all from the progressive dysfunction of a single systemic ventricle and the lack of a subpulmonary chamber ensuring pulsatile pulmonary flow. Although the Fontan operation in many patients with an univentricular heart is a very good method of palliative treatment, which undoubtedly extends the survival of children born with this heart defect, it also inevitably leads to severe complications developing over the years. Patients after the Fontan operation are also characterized by a significant reduction in exercise capacity, which is observed both in clinical practice in reference centres dealing with patients with congenital heart defects, and in multi-centre studies. Among other things, it was shown that children after the Fontan operation obtained 30% lower values of peak oxygen uptake in the ergospirometric test compared to the control group of healthy children (Amadero P et al., Heart 2018). The reduced exercise capacity of patients and the development of Fontan circulatory complications affect both the quality of life and the prognosis of adult patients with univentricular heart.

    phase 3 small molecule active

    1 trial

  19. Topotecan HEXAL 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Anastrozol STADA® 1 mg Filmtabletten, Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, VS-6766, LETRO-cell® 2,5 mg Filmtabletten, VS-6063, Letrozol - 1 A Pharma® 2,5 mg Filmtabletten, ZOLSKETIL pegylated liposomal 2 mg/mL concentrate for dispersion for inf

    Vera Therapeutics

    Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

    phase 3 small molecule active

    1 trial

  20. Vibegron, Vibegron, Vibegron, Vibegron, Vibegron, Vibegron, Vibegron

    Pharma Mar S.A.

    Neurogenic Detrusor Overactivity (NDO)

    phase 3 small molecule active

    1 trial

  21. Xylocore Medium Strength, bicaVera 4,25 % Glucose, 1,75 mmol/l Calcium, Peritonealdialyselösung, Xylocore High Strength, PHYSIONEAL 40 Glucose 3,86 % w/v / 38,6 mg/ml, Peritonealdialyselösung, balance 4,25% Glucose, 1,75 mmol/l Calcium, Peritonealdialyselösung, PHYSIONEAL 35 Glucose 1,36 % w/v / 13,6 mg/ml, Peritonealdialyselösung, FIXIONEAL “35 Glucosio 3,86% p/v/38,6 mg/ml” in sacca Clear-Flex Soluzione per dialisi peritoneale, balance 2,3% Glucose, 1,75 mmol/l Calcium, Peritonealdialyselösung, PHYSIONEAL

    Pharma Mar S.A.

    End-Stage Kidney Disease

    phase 3 small molecule active

    1 trial

  22. Analogs, Prostaglandin E1

    Vera Therapeutics

    Covid19

    phase 2 small molecule terminated

    1 trial

  23. Atacicept

    Vera Therapeutics

    IgA Nephropathy (IgAN); Berger Disease; Renal and Urinary Disorders

    phase 2 small molecule active

    1 trial

  24. Atacicept

    Vera Therapeutics

    pMN

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources